M.D. (Academy of Military Medical Sciences)

Zheng ZHNAG is the director of the Institute for Hepatology at Shenzhen Third Pepole’s Hospital, Guangdong, China. He received his doctoral degree (M.D. and PhD) in Immunology and the Infectious Diseases in the Beijing Academy of Military Medical Sciences, Beijing, China (2005). Then he received his postdoc training from the University of North Carolina at Chapel Hill (UNC-CH) from 2009-2010 and 2013-2014. He has focused on clinical immunology, pathogenesis and immune therapy (including mesenchymal stem cell treatment) in pathogen infection including SARS-CoV-2, HBV, HIV-1 and Tb in humans. He obtained several grants from the National Grand Program on Key Infectious Disease, National Key Basic Research Program of China and National Science Fund for Distinguished Young Scholars as well as National Natural Science Foundation of China, et al. He currently focuses on the translational study from clinical immune characterization to immune intervention in patients with chronic HBV, HIV and Tb infection in clinic. He has published more than 90 papers as first/corresponding authors in Nature, Cell, Nat Med, Cell Res, Nat Commun, Sci Adv, J Clin Invest, Gastroenterology, Blood, Hepatology and so on.

1.    Ju B#, Zhang Q#, Ge S, Wang R, Yu J, Shan S, Zhou B, Song S, Tang X, Yu J, Ge J, Lan J, Yuan J, Wang H, Zhao J, Zhang S, Wang Y, Shi X, Liu L, Wang X, Zhang Z*, Zhang L*. Potent human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature, 2020, 584(7819):115-119.
2.    Zhang Q#, Ju B#, Ge J#, Chan JF#, Cheng L#, Wang R#, Huang W#, Fang M, Chen P, Zhou B, Song S, Shan S, Yan B, Zhang S, Ge X, Yu J, Zhao J, Wang H, Liu L, Lv Q, Fu L, Shi X, Yuen KY, Liu L, Wang Y*, Chen Z*, Zhang L*, Wang X*, Zhang Z*. Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. Nat Communications, 2021, 12:4210.
3.    Bost P#, Giladi A#, Liu Y#, Bendjelal Y, Xu G, David E, Blecher-Gonen R, Cohen M, Medaglia C, Zhang S, Schwikowski B*, Zhang Z*, Amit I*. Host-viral infection maps reveal signatures of severe COVID-19 patients. Cell, 2020, 181(7):1475-1488. 
4.    Liao M#, Liu Y#, Yuan J#, Wen Y, Xu G, Zhao J, Cheng L, Li J, Wang X, Wang F, Liu L*, Ido A*, Zhang S*, Zhang Z*. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med, 2020, 26(6):842-844.
5.    Zhao J#, Yuan Q#, Wang H#, Liu W#, Liao X#, Su Y#, Wang X, Yuan J, Li T, Li J, Qian S, Hong C, Wang F, Liu Y, Wang Z, He Q, Li Z, He B, Zhang T, Ge S*, Liu L*, Zhang J*, Xia N, Zhang Z*. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis, 2020, 71(16):2027-2034. 
6.    Tang X, Zhang S, Peng Q, Ling L, Shi H, Liu Y, Cheng L, Xu L, Cheng L, Chakrabarti LA, Chen Z, Wang H, Zhang Z*. Sustained IFN-I Stimulation Impairs MAIT Cell Responses to Bacteria by Inducing IL-10 during chronic HIV-1 Infection. Sci Adv, 2020,6(8):eaaz0374. 
7.    Zhang Z#*, Cheng L#, Zhao J#, Li G, Zhang L, Chen W, Nie W, Reszka-Blanco N, Wang FS*, Su L*. Plasmacytoid dendritic cells promote HIV-1-induced group-3 innate lymphoid cell depletion. J Clin Invest, 2015, 125(9):3692–3703.
8.    Xu X#, Shang Q#, Chen X#, Nie W, Zou Z, Huang A, Meng M, Jin L, Xu R, Zhang JY, Fu J, Wang L, Tang Z, Xie Y, Yang X, Zhang Z*, Wang FS*. Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients. Cell Mol Immunol, 2015, 12: 309-316.
9.    Zhang Z#, Zhang S#, Zou Z#, Shi J, Zhao J, Fan R, Qin E, Li B, Li Z, Xu X, Fu J, Zhang J, Gao B, Tian Z,Wang FS*. Hyper–Cytolytic Activity of Hepatic Natural Killer Cells Correlates with Liver Injury in Chronic Hepatitis B Patients. Hepatology, 2011, 53(1): 73-85. 
10.    Zhang Z#, Zhang JY#, Wherry EJ, Jin B, Xu B, Zou, ZS, Zhang SY, Li BS, Wang HF, Wu H, Fu YX, Wang FS. Dynamic programmed death-1 expression on virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology, 2008, 134: 1938-1949.